Catheter Precision to Attend and Participate in the Western Atrial Fibrillation Symposium
Catheter Precision (NYSE/American: VTAK) has announced its participation in the 18th Western Atrial Fibrillation Symposium from February 27 – March 1 in Salt Lake City, Utah. The symposium, featuring over 80 world-renowned faculty members, focuses on improving atrial fibrillation (AF) outcomes globally through discussions of latest diagnostic and treatment advancements.
The company aims to showcase its LockeT product line, which serves as an adjunctive solution for atrial fibrillation procedures. CEO David Jenkins emphasized that attending industry-specific meetings is important to their commercialization strategy, with the goal of educating physicians about LockeT's benefits for recovery room staff, hospitals, and patients.
Catheter Precision (NYSE/American: VTAK) ha annunciato la sua partecipazione al 18° Simposio sulla Fibrillazione Atriale Occidentale, che si terrà dal 27 febbraio al 1 marzo a Salt Lake City, Utah. Il simposio, che presenta oltre 80 membri di facoltà di fama mondiale, si concentra sul miglioramento degli esiti della fibrillazione atriale (AF) a livello globale attraverso discussioni sulle ultime innovazioni diagnostiche e terapeutiche.
L'azienda punta a presentare la sua linea di prodotti LockeT, che funge da soluzione complementare per le procedure di fibrillazione atriale. Il CEO David Jenkins ha sottolineato che partecipare a incontri specifici del settore è importante per la loro strategia di commercializzazione, con l'obiettivo di educare i medici sui benefici di LockeT per il personale delle sale di recupero, gli ospedali e i pazienti.
Catheter Precision (NYSE/American: VTAK) ha anunciado su participación en el 18º Simposio de Fibrilación Auricular Occidental que se llevará a cabo del 27 de febrero al 1 de marzo en Salt Lake City, Utah. El simposio, que contará con más de 80 miembros de la facultad de renombre mundial, se centra en mejorar los resultados de la fibrilación auricular (AF) a nivel global a través de discusiones sobre los últimos avances en diagnóstico y tratamiento.
La empresa tiene como objetivo presentar su línea de productos LockeT, que sirve como una solución complementaria para los procedimientos de fibrilación auricular. El CEO David Jenkins enfatizó que asistir a reuniones específicas de la industria es importante para su estrategia de comercialización, con el objetivo de educar a los médicos sobre los beneficios de LockeT para el personal de las salas de recuperación, los hospitales y los pacientes.
Catheter Precision (NYSE/American: VTAK)는 2월 27일부터 3월 1일까지 유타주 솔트레이크시티에서 열리는 제18회 서부 심방세동 심포지엄에 참여한다고 발표했습니다. 80명 이상의 세계적 권위자들이 참석하는 이 심포지엄은 최신 진단 및 치료 발전에 대한 논의를 통해 전 세계적으로 심방세동(AF) 결과를 개선하는 데 중점을 두고 있습니다.
회사는 심방세동 절차를 위한 보조 솔루션으로 작용하는 LockeT 제품군을 선보일 계획입니다. CEO David Jenkins는 산업별 회의에 참석하는 것이 그들의 상업화 전략에 중요하며, LockeT가 회복실 직원, 병원 및 환자에게 제공하는 이점을 의사들에게 교육하는 것이 목표라고 강조했습니다.
Catheter Precision (NYSE/American: VTAK) a annoncé sa participation au 18ème Symposium de Fibrillation Auriculaire de l'Ouest, qui se tiendra du 27 février au 1er mars à Salt Lake City, Utah. Le symposium, qui met en vedette plus de 80 membres de la faculté de renommée mondiale, se concentre sur l'amélioration des résultats de la fibrillation auriculaire (FA) à l'échelle mondiale à travers des discussions sur les dernières avancées diagnostiques et thérapeutiques.
L'entreprise vise à présenter sa gamme de produits LockeT, qui sert de solution complémentaire pour les procédures de fibrillation auriculaire. Le PDG David Jenkins a souligné que la participation à des réunions spécifiques à l'industrie est importante pour leur stratégie de commercialisation, avec pour objectif d'éduquer les médecins sur les avantages de LockeT pour le personnel des salles de réveil, les hôpitaux et les patients.
Catheter Precision (NYSE/American: VTAK) hat seine Teilnahme am 18. Westlichen Vorhofflimmern-Symposium vom 27. Februar bis 1. März in Salt Lake City, Utah, angekündigt. Das Symposium, das über 80 weltweit renommierte Fakultätsmitglieder präsentiert, konzentriert sich darauf, die Ergebnisse von Vorhofflimmern (AF) weltweit durch Diskussionen über die neuesten diagnostischen und therapeutischen Fortschritte zu verbessern.
Das Unternehmen plant, seine LockeT-Produktlinie vorzustellen, die als ergänzende Lösung für Verfahren zur Vorhofflimmern dient. CEO David Jenkins betonte, dass die Teilnahme an branchenspezifischen Treffen wichtig für ihre Kommerzialisierungsstrategie ist, mit dem Ziel, Ärzte über die Vorteile von LockeT für das Personal im Aufwachraum, für Krankenhäuser und für Patienten zu informieren.
- None.
- None.
FORT MILL, S.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced their attendance at the 18th Western Atrial Fibrillation Symposium from February 27 – March 1 in Salt Lake City, Utah.
Western AF is an internationally recognized meeting focused on improving atrial fibrillation (AF) outcomes worldwide. Led by more than 80 world-renowned faculty who will discuss the latest advancements in diagnosis and treatment, the program includes challenging case studies, engaging panel discussions, and topic-focused roundtables for interactive learning.
David Jenkins, CEO of Catheter Precision, said, “Attendance at industry specific meetings is part of our commercialization strategy. Western AF is well attended by leading experts in the field of atrial ablation and our LockeT product line is an attractive adjunctive piece for the atrial fibrillation procedure. Our hope is to introduce and educate physicians on LockeT and the many benefits it can provide their recovery room staff, the hospital, and most importantly, the patients.”
About LockeT
Catheter Precision’s LockeT is a suture retention device intended to assist in hemostasis after vascular catheter access. LockeT is a Class 1 device registered with the FDA.
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov.
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
CONTACTS:
At the Company
David Jenkins
973-691-2000
info@catheterprecision.com
# # #
FAQ
What is the significance of Catheter Precision (VTAK) attending the Western AF Symposium 2025?
When and where is the 18th Western Atrial Fibrillation Symposium taking place?
What is the focus of VTAK's LockeT product line presentation at the Western AF Symposium?
How many faculty members are participating in the 2025 Western AF Symposium?
What educational formats are included in the Western AF Symposium 2025?
